Latigo Biotherapeutics Inc., a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines, has appointed Nima Farzan, MBA, as chief executive officer (CEO). Farzan brings a strong track record of more than two decades of leadership experience in the biopharmaceutical industry. He replaces Desmond Padhi, Pharm.D., operating partner at Westlake Village BioPartners, who has been serving as Latigo’s interim CEO. “The addition of Nima represents a pivo...